Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL336, a First-in-class Long-acting ...

Five Phase 2 studies ongoing in China in Chronic Obstructive Pulmonary Disorder, asthma, Chronic Rhinosinusitis with Nasap Polyps, Chronic Spontaneous Urticaria and AD. Belenos Biosciences Inc., a ...
TMCnet

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity ...

The presentation, to be delivered by Dr. Man-Fung Yuen, Chair Professor of Gastroenterology and Hepatology at The University of Hong Kong, features new data from nine patients across 22 doses in the ...